All News

The pandemic’s aftermath left lasting tensions in health care.

The analysis shows patients achieved deep and durable responses despite being ineligible for the CARTITUDE-1 trial.

Pharmacists play a vital role in patient advocacy and health care collaboration by ensuring safe medication management, facilitating seamless care transitions, providing education, promoting adherence, and fostering compassion to enhance therapeutic outcomes and patient wellness.

Examining the clinical applications, effectiveness, safety, and regulation of herbal supplements with a focus on the role of pharmacists.

Early diagnosis of chronic kidney disease (CKD) can help optimize treatment and manage the disease to prevent further decline.

Pharmacies can strategically invest in AI technologies to streamline operations and improve patient care while addressing cost challenges and maximizing return on investment in 2025.

Fiber-rich foods show improvements in health and reductions in chronic diseases, including obesity, by promoting weight management and enhancing the metabolism.

Treatment with IVIG leads to high responses 6 months following the initiation of therapy.

However, the effects on patient-reported outcomes were inconclusive when compared with self-monitoring blood glucose or the usual care.

Pharmacy students can provide education, patient advocacy, and medication access.

New medications like glucagon-like peptide-1 agonists and resmetirom show promise in reversing fatty liver disease and preventing progression.

Pharmacists should be aware of the impacts that anemia in patients being treated for cancer has on daily activities and overall quality of life.

Compliance is achievable for outpatient oncology practices with careful planning and execution.

Adherence to thiopurine medications after 6 months of use was 87.9% under direct pharmacist care but 65.7% under general practitioner guidance.

Certain laboratory tests indicate stronger predictions for hospital stay, suggesting pharmaceutical intervention could help reduce the length of cardiovascular-related hospital stay.

Patients with hormone receptor–positive and human epidermal growth factor receptor 2 breast cancer are particularly at risk.

Investigators did not report serious adverse events or deaths related to depemokimab in either of the 2 phase 3a clinical trials.

Immunocompromised older adults developed fewer antibodies against RSV following vaccination compared with immunocompetent individuals.

Patients with relapsed, refractory disease achieved deep, durable responses with equecabtagene autoleucel.

Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.

Although each of the product samples of phenibut contained the actual active ingredient, the exact amount of the active ingredient was inaccurate and, in one sample, found to be at a higher dose.

The model, Deep-IO, shows improved specificity and sensitivity compared with existing predictive biomarkers.

The regulatory decision marks a significant step forward in the treatment of non-tuberculous mycobacteria infections.

Treatment options may include treating the anemia with blood transfusions, androgen therapy, thalidomide, and other medications.

Tislelizumab is approved in combination with platinum and fluoropyrimidine-based chemotherapy as first-line treatment of unresectable or metastatic HER2-negative tumors.

Pharmacists can educate patients on controlling risk factors and stay up-to-date on emerging therapies like SGLT2 inhibitors and finerenone that can slow disease progression.

The approval offers patients with solid tumors an alternative to intravenous PD-1 inhibitor administration.